Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

145.43 +1.75 (+1.22%)
Streaming Delayed Price Updated: 9:36 AM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence
Looking Into Biogen's Recent Short Interest
 
Via Benzinga
1 of Wall Street’s Favorite Stock Worth Your Attention and 2 That Underwhelm
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Economy
UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression
Via Stocktwits
Biogen (BIIB) Stock Trades Down, Here Is Why
Shares of biotech company Biogen (NASDAQ:BIIB) fell 3% in the afternoon session after Needham analyst Ami Fadia reiterated a "Hold" rating on the stock. This rating suggests the analyst expects the... 
Via StockStory
Topics Artificial Intelligence
Beyond The Numbers: 10 Analysts Discuss Biogen Stock
 
Via Benzinga
Market Monitor News September 3 BMO - Tech Slammed, Yields Spike, Trump Stirring the Pot Again
Wall Street kicked off September on shaky ground as rising bond yields pressured tech stocks and legal turmoil over Trump’s tariffs added fresh uncertainty. Meanwhile, investors brace for Friday’s key... 
Via Chartmill
Topics Bonds Economy Government
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive,... 
From Biogen Inc.
Via GlobeNewswire
Biogen (BIIB) Stock Is Up, What You Need To Know
Shares of biotech company Biogen (NASDAQ:BIIB) jumped 4.8% in the afternoon session after the company and its partner Eisai received FDA approval for a weekly subcutaneous injection of their... 
Via StockStory
Topics Economy
Tuesday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
VIX Jumps 20% As Stocks Slump, Gold Tops Record Highs: What's Moving Markets Tuesday?
Wall Street stumbled on Tuesday, with broad losses by midday in New York as investors turned risk-off amid mounting concerns over lofty valuations, seasonal headwinds and fiscal strains. 
Via Benzinga
Topics Stocks
Stay informed with the top movers within the S&P500 index on Tuesday.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
3 Mid-Cap Stocks That Concern Us
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment
This could put pressure on Eli Lilly, which sells a competing drug called Kisunla. 
Via Investor's Business Daily
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
From Biogen Inc.
Via GlobeNewswire
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
Reflecting On Therapeutics Stocks’ Q2 Earnings: Moderna (NASDAQ:MRNA)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Moderna... 
Via StockStory
Topics Artificial Intelligence
1 S&P 500 Stock on Our Watchlist and 2 Facing Headwinds
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to be removed soon. 
Via Benzinga
Topics Stocks
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Biogen Inc.
Via GlobeNewswire
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
From Biogen Inc.
Via GlobeNewswire
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs... 
Via Benzinga
Topics Government World Trade
2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
Wondering what's happening in today's S&P500 pre-market session?
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.